Drug Profile
Metformin/rosuvastatin - Jeil Pharmaceutical
Alternative Names: JLP 1310; Metformin hydrochloride/rosuvastatin calcium - Jeil PharmaceuticalLatest Information Update: 08 Oct 2021
Price :
$50
*
At a glance
- Originator Jeil Pharmaceutical
- Class Antihyperglycaemics; Antihyperlipidaemics; Biguanides; Cardiovascular therapies; Fluorobenzenes; Pyrimidines; Small molecules; Sulfonamides
- Mechanism of Action AMP activated protein kinase stimulants; Gluconeogenesis inhibitors; HMG-CoA reductase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Cardiovascular disorders; Dyslipidaemias; Type 2 diabetes mellitus
Most Recent Events
- 08 Oct 2021 Clinical development is still ongoing for Cardiovascular disorders, Dyslipidaemias, Type 2 diabetes mellitus (Jeil Pharmaceutical pipeline, October 2021)
- 28 Jan 2019 Chemical structure information added
- 01 Oct 2018 Jeil Pharmaceutical initiates a phase I trial in Healthy volunteers in South Korea (PO) (NCT03690778)